openPR Logo
Press release

United States Oral Contraceptive Pills Market to Reach USD 38.16 Billion by 2033, Driven by Telemedicine Expansion and Product Innovation | DataM Intelligence

10-14-2025 11:23 AM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Oral Contraceptive Pills Market

Oral Contraceptive Pills Market

The global Oral Contraceptive Pills Market reached USD 19.85 Billion in 2024 and is projected to reach USD 38.16 Billion by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Bayer AG received FDA approval for its next-generation oral contraceptive with reduced side effects and improved cycle control.
✅ In October 2025, The American College of Obstetricians and Gynecologists issued new guidelines supporting over-the-counter access to oral contraceptives.
✅ In October 2025, Nurx expanded its telemedicine platform to offer personalized oral contraceptive prescriptions in all 50 states.

Japan: Recent Industry Developments

✅ In October 2025, Japan's Ministry of Health approved the first low-dose oral contraceptive specifically designed for Asian populations.
✅ In October 2025, Takeda Pharmaceutical launched a digital health platform integrating oral contraceptive management with menstrual cycle tracking.
✅ In October 2025, A consortium of Japanese healthcare providers initiated a nationwide awareness campaign about oral contraceptive options.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/oral-contraceptive-pills-market?jd

Market Trends & Drivers

The Oral Contraceptive Pills Market is experiencing steady growth driven by increasing awareness about family planning, rising female education and employment rates, and technological advancements in formulation. Key trends include the development of personalized contraceptives, expansion of telemedicine services, and growing preference for low-dose and extended-cycle formulations. The increasing focus on women's healthcare, coupled with regulatory approvals for innovative products and improved access through digital platforms, is significantly accelerating market expansion.

Competitive Landscape

The market features strong competition among pharmaceutical giants and specialized women's healthcare companies.

Bayer AG leads the market with its extensive oral contraceptive portfolio including Yaz, Yasmin, and new generation formulations.
Pfizer Inc. maintains a significant market presence with established brands and ongoing research in women's health.
Johnson & Johnson (through its subsidiary Janssen) offers comprehensive contraceptive solutions including oral formulations.
Merck & Co., Inc. (Organon) specializes in women's health with a diverse portfolio of contraceptive products.
AbbVie Inc. (Allergan) provides oral contraceptives through its established women's healthcare division.
Viatris Inc. offers affordable generic oral contraceptive options across global markets.
Teva Pharmaceutical Industries Ltd. is a leading provider of generic oral contraceptives with extensive market coverage.
Lupin Limited expands its oral contraceptive portfolio with focus on emerging markets and specialized formulations.
Glenmark Pharmaceuticals develops innovative oral contraceptive formulations and delivery systems.
HRA Pharma (Perrigo Company) focuses on women's health with specialized contraceptive products.

Segmentation

By Type (Combination, Progestin-Only, Others)
By Category (Branded, Generics)
By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oral-contraceptive-pills-market?jd

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a market research and consulting firm that bridges the gap between data and decisive action. We specialize in translating top market trends and in-depth analysis into swift, smart solutions for your business.
With a repository of 6,300+ reports across 40+ industries, we provide the robust intelligence that over 200 companies in 50+ countries rely on to power their growth.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release United States Oral Contraceptive Pills Market to Reach USD 38.16 Billion by 2033, Driven by Telemedicine Expansion and Product Innovation | DataM Intelligence here

News-ID: 4222928 • Views:

More Releases from DataM intelligence 4 Market Research LLP

United States Sickle Cell Anaemia Testing Market 2025 | Growth Drivers, Competitive Landscape & Investment Opportunities
United States Sickle Cell Anaemia Testing Market 2025 | Growth Drivers, Competit …
Market Size and Growth Sickle Cell Anaemia Testing Market is expected to reach at a high CAGR during the forecast period (2024-2031). Key Development: United States: Recent Industry Developments ✅ In October 2025, Terumo Blood and Cell Technologies and Hemex Health announced the expansion of their Gazelle® diagnostic platform, now available in over 40 countries. This portable, low-cost device enables rapid identification of hemoglobin variants, aiding in the diagnosis of sickle cell and beta
United States Human Papillomavirus (HPV) Vaccines Market to Reach USD 12.36 Billion by 2033, Led by Merck, GSK, and Walvax Biotechnology | DataM Intelligence
United States Human Papillomavirus (HPV) Vaccines Market to Reach USD 12.36 Bill …
The global Human Papillomavirus (HPV) Vaccines Market reached USD 3,043.19 Million in 2024 and is projected to reach USD 12,361.15 Million by 2033, growing at a CAGR of 16.9% during the forecast period 2025-2033, according to DataM Intelligence. United States: Recent Industry Developments ✅ In October 2025, The CDC expanded HPV vaccination recommendations to include adults up to age 45, significantly increasing the eligible population. ✅
United States Health Insurance Market Projected to Expand at 5.2% CAGR, Reaching USD 2.40 Trillion by 2031, Led by UnitedHealth, Anthem, and Kaiser Permanente | DataM Intelligence
United States Health Insurance Market Projected to Expand at 5.2% CAGR, Reaching …
The global Health Insurance Market reached USD 621.35 billion in 2023 and is projected to reach USD 2408.49 billion by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031, according to DataM Intelligence. United States: Recent Industry Developments ✅ In October 2025, UnitedHealth Group launched a new AI-powered platform for personalized premium calculations and real-time claims processing. ✅ In October 2025, The Centers for Medicare & Medicaid
Peptide Therapeutics Market Growth Outlook 2024-2031: Innovations, Key Players, and Future of Targeted Drug Development
Peptide Therapeutics Market Growth Outlook 2024-2031: Innovations, Key Players, …
Recent market intelligence suggests that the Peptide Therapeutics Market is expected to grow at a compound annual growth rate (CAGR) of around 7.8% between 2024 and 2031. The market is segmented by type (patented vs generic), route of administration (oral, parenteral), synthesis technology (solid-phase, liquid, hybrid), and application area (cancer, metabolic, cardiovascular, CNS, infectious diseases). The North America region currently commands the largest share owing to robust biopharma R&D investment,

All 5 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the